Helen Elizabeth Hanby
Director/Board Member chez NIGHTSTAR THERAPEUTICS PLC
Profil
Helen Elizabeth Hanby currently works at NightstaRx Ltd., as Secretary & Director from 2019, Nightstar Therapeutics Ltd., as Secretary & Director from 2019, and Tungsten Bidco Ltd., as Secretary & Director from 2019.
Postes actifs de Helen Elizabeth Hanby
| Sociétés | Poste | Début |
|---|---|---|
| NIGHTSTAR THERAPEUTICS PLC | Director/Board Member | 07/06/2019 |
Tungsten Bidco Ltd.
 Tungsten Bidco Ltd. Financial ConglomeratesFinance Founded in 2019, Tungsten Bidco Ltd. is a British company that functions as an investment holding company. Part of Biogen, Inc., the private company is based in Maidenhead, UK. | Director/Board Member | 04/06/2019 |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Director/Board Member | 07/06/2019 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Tungsten Bidco Ltd.
Tungsten Bidco Ltd. Financial ConglomeratesFinance Founded in 2019, Tungsten Bidco Ltd. is a British company that functions as an investment holding company. Part of Biogen, Inc., the private company is based in Maidenhead, UK. | Finance |
